Announcement • Jul 24
MediciNova, Inc. to Report Q2, 2026 Results on Aug 14, 2026 MediciNova, Inc. announced that they will report Q2, 2026 results on Aug 14, 2026 Announcement • Jul 15
Medicinova Achieves Target Enrollment in Seanobi-Als Study Evaluating Mn-166 (Ibudilast) in Als Patients MediciNova announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) evaluating MN-166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS). The Expanded Access Program SEANOBI study is funded by National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH) supported under the ACT for ALS. This program is designed to provide MN-166 (ibudilast) to individuals living with ALS who are not eligible to participate in ongoing randomized clinical trials. Reaching this enrollment milestone reflects the strong engagement of the ALS community and the dedicated efforts of patients, families, investigators, and clinical staff involved in the program. Active participants in the SEANOBI-ALS study remain on-track with treatment and protocol-specified follow-ups. Final patient follow-ups are projected to conclude in early 2027, triggering the data analysis phase to support upcoming scientific presentations and peer-reviewed publications by an academic lead investigator. MN-166 (ibudilast) is an orally available small-molecule inhibitor of phosphodiesterase-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). The compound is currently being evaluated across multiple neuroinflammatory and neurodegenerative indications, including ALS. MediciNova announced in September 2025 that it successfully completed enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial of MN-166. MN-166 (ibudilast) is an orally available small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). MediciNova holds Orphan Drug Designation for MN-166 (ibudilast) in ALS by U.S. FDA and EU EMA. MN-166 (ibudilast) has received Fast Track Designation by FDA for treatment of ALS. In addition, MN-166 (ibudilast) holds Orphan Disease Designation for the treatment of Glioblastoma. Live News • Jul 02
MediciNova Completes Phase 2 Milestone and Gains Key Patent Allowance MediciNova reported that the last patient last visit has been completed in its Phase 2 trial of MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes, with initial data expected in Q3 2026. The company is also advancing the SEANOBI Phase 2 ALS study, which has reached 100 of 200 planned patients enrolled, and has received a U.S. patent allowance for MN-166 in combination with an anti-PD-1 antibody for glioblastoma.
The patent allowance expands MediciNova’s intellectual property around MN-166 in oncology, and the ALS enrollment update provides more visibility on the company’s clinical execution across multiple indications.
MediciNova’s stock last traded at US$1.42, with the year-to-date return at 6.8%.
Taken together, the clinical milestones and new patent protection underscore that a significant portion of MediciNova’s outlook is linked to trial outcomes and regulatory progress, so timelines, data quality and future funding remain central risks to monitor. 
